The DOI matches its Crossref record.
Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy.
Abstract
To determine the frequency and prognostic importance of pretreatment clinical characteristics in patients currently undergoing treatment for stage III non-small-cell lung cancer (NSCLC), data were collected on 378 patients receiving high-dose (120 mg/m2) cisplatin plus vinca alkaloid combination chemotherapy regimens since 1978. Variables analyzed included age, sex, weight loss, performance status, histologic subtype, presence of extrathoracic metastases, number of metastatic organ sites, presence of liver, bone, or brain involvement, prior radiation or surgery, and serum lactate dehydrogenase (LDH). The effect of a major response to chemotherapy on survival was also investigated. Using multivariable analyses, the following were found to be associated with outcome: initial performance status, with patients having a performance status of 80% to 100% having an increased major objective response rate and survival; bone metastases, which were adversely predictive of response rate and survival; elevated serum LDH and male sex, both of which were associated with shortened survival and remission duration; and the presence of two or more extrathoracic metastatic organ sites, which was associated with shorter survival. When major objective response with chemotherapy was included in a conditional multivariable analysis, it was strongly associated with longer median survival. Information from this analysis may be useful when comparing the response data of completed studies in similar patients, in designing future trials, and in the selection of cisplatin plus vinca alkaloid therapy for individual patients with advanced NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Self-citationMiller, V. A., Kris, M. G., Shah, N., Patel, J., Azzoli, C., Gomez, J., Krug, L. M., Pao, W., Rizvi, N., Pizzo, B., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.158 · Cited by 730
Self-citationAlbain, K. S., Crowley, J. J., LeBlanc, M., & Livingston, R. B. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1618 · Cited by 728
Mechanisms of resistance to cisplatin and carboplatin
Stewart, D. J. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.02.001 · Cited by 631
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
Ross, P. J., Ashley, S., Norton, A., Priest, K., Waters, J. S., Eisen, T., Smith, I. E., & O'Brien, M. E. R. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601781 · Cited by 476
Metadata
- Authors
- O'Connell, J. P., Kris, M. G., Gralla, R. J., Groshen, S., Trust, A., Fiore, J. J., Kelsen, D. P., Heelan, R. T., & Golbey, R. B.
- Venue
- Journal of Clinical Oncology
- Published
- 1986-11
- Volume
- 4
- Issue
- 11
- Pages
- 1604-1614
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1803099259
- Cited by
- 238
- References
- 0
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. https://app.cochat.ai/papers/10.1200/jco.1986.4.11.1604
- The paper
- O'Connell, J. P., Kris, M. G., Gralla, R. J., Groshen, S., Trust, A., Fiore, J. J., Kelsen, D. P., Heelan, R. T., & Golbey, R. B. (1986). Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1986.4.11.1604
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.